|  |  |  |
| --- | --- | --- |
| **Antigen** | **Indications** | **References** |
| SPAG9 | CRCRCC | (*1*)(*2*) |
| AKAP4 | CRC | (*3*) |
| BORIS | MelanomaCRC HNSCC | (*4*)(*5*)(*6*) |
| Survivin | MelanomaLung(NSCLC)CRC BladderGliomaRCC | (*7*)(*8*)(*9*)(*10*)(*11*)(*12*) |
| MAGE-A1 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCCRCC | (*13*)(*14*)(*15*)(*16*)(*17*)(*6*)(*18*) |
| PRAME | MelanomaLung(NSCLC)BladderHNSCCRCC | (*19*)(*20*)(*21*)(*6*)(*22*) |
| CT45 | MelanomaLung(NSCLC)CRCGliomaHNSCC | (*23*)(*24*)(*15*)(*25*)(*26*) |
| NY-SAR-35 | MelanomaLung(NSCLC)Bladder | (*27*)(*27*)(*27*) |
| FSIP1 | Bladder | (*28*) |
| HOM-TES-85 | Lung(NSCLC)HNSCC | (*29*)(*30*) |
| NY-BR-1 | Breast Cancer | (*31*) |
| MAGE-A9 | MelanomaBladderRCCHNSCC | (*13*)(*32*)(*33*)(*34*) |
| SCP-1 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCC | (*35*)(*36*)(*15*)(*37*)(*38*)(*30*) |
| MAGE-A12 | MelanomaBladderGliomaHNSCCRCC | (*13*)(*39*)(*25*)(*40*)(*41*) |
| MAGE-A10 | MelanomaCRCBladderGliomaHNSCC | (*13*)(*42*)(*43*)(*17*)(*6*) |
| GATA-3 | RCCHNSCC | (*44*)(*45*) |
| GAGE-7 | MelanomaCRC | (*13*)(*46*) |
| SSX-4 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCC | (*47*)(*48*)(*48*)(*37*)(*38*)(*6*) |
| SPANXC | MelanomaLung(NSCLC)CRCBladderHNSCC | (*49*)(*49*)(*49*)(*49*)(*40*) |
| CT46 | Bladder | (*50*) |
| MAGE-A3 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCCRCC | (*51*)(*52*)(*15*)(*21*)(*17*)(*6*)(*18*) |
| MAGE-C2 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCC | (*53*)(*54*)(*15*)(*55*)(*17*)(*6*) |
| TSP50 | Lung(NSCLC)CRC | (*56*)(*57*) |
| EpCAM | Lung(NSCLC)CRCBladderRCC | (*58*)(*9*)(*59*)(*60*) |
| CAGE | Lung(NSCLC)CRCHNSCC | (*61*)(*62*)(*26*) |
| MAGE-A8 | MelanomaCRCBladder | (*13*)(*63*)(*64*) |
| FBXO39 | Lung(NSCLC)CRCRCC | (*65*)(*65*)(*65*) |
| PAGE-4 | Lung(NSCLC) | (*66*) |
| MAGE-A6 | MelanomaCRCBladderRCC | (*13*)(*15*)(*67*)(*68*) |
| BAGE-4 | CRCBladderGliomaHNSCC  | (*46*)(*69*)(*17*)(*6*) |
| MAGE-C1 | MelanomaLung(NSCLC)CRCBladderHNSCC | (*53*)(*70*)(*15*)(*55*)(*30*) |
| NY-ESO-1 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCCRCC | (*71*)(*72*)(*15*)(*21*)(*17*)(*6*)(*73*) |
| MAGE-A2 | MelanomaCRCBladderGliomaHNSCCRCC | (*74*)(*15*)(*75*)(*76*)(*77*)(*18*) |
| XAGE-1 | MelanomaLung(NSCLC)GliomaHNSCC | (*78*)(*79*)(*80*)(*81*) |
| MAGE-A11 | MelanomaGliomaHNSCC | (*13*)(*25*)(*82*) |
| SSX-2 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCC | (*47*)(*48*)(*48*)(*37*)(*38*)(*6*) |
| LAGE-1 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCC | (*83*)(*29*)(*84*)(*21*)(*17*)(*6*) |
| MAGE-A4 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCCRCC | (*85*)(*86*)(*15*)(*87*)(*17*)(*6*)(*18*) |
| MAGE-A5 | MelanomaLung(NSCLC)CRCHNSCC | (*13*)(*88*)(*15*)(*89*) |
| MAGE-B2 | MelanomaLung(NSCLC)HNSCC | (*90*)(*90*)(*91*) |
| MAGE-B1 | MelanomaLung | (*90*)(*90*) |
| HAGE | MelanomaLung(NSCLC)CRCBladderHNSCCRCC | (*92*)(*92*)(*15*)(*92*)(*93*)(*92*) |
| SSX-1 | MelanomaLung(NSCLC)CRCBladderGliomaHNSCC | (*47*)(*48*)(*48*)(*37*)(*76*)(*30*) |
| NXF2 | MelanomaLung(NSCLC)CRCBladderHNSCC | (*94*)(*94*)(*94*)(*94*)(*26*) |
| SAGE | MelanomaLung(NSCLC)BladderGliomaHNSCC | (*92*)(*92*)(*92*)(*25*)(*26*) |
| LEMD1 | CRCGlioma | (*95*)(*25*) |
| OY-TES-1 | Lung(NSCLC)CRCBladder | (*96*)(*96*)(*96*) |
| LDHC | MelanomaLung(NSCLC)Glioma | (*97*)(*29*)(*25*) |

CRC: Colorectal Cancer, HNSCC: Head and Neck Squamous Cell Carcinoma, NSCLC*:* Non-Small Cell Lung Cancer, RCC: Renal Cell Cancer

1. D. Kanojia, M. Garg, S. Gupta, A. Gupta, A. Suri, Sperm-Associated Antigen 9 Is a Novel Biomarker for Colorectal Cancer and Is Involved in Tumor Growth and Tumorigenicity. *The American Journal of Pathology* **178**, 1009-1020 (2011).

2. M. Garg, D. Kanojia, A. Khosla, N. Dudha, S. Sati, D. Chaurasiya, N. Jagadish, A. Seth, R. Kumar, S. Gupta, A. Gupta, N. K. Lohiya, A. Suri, Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. *Cancer Res* **68**, 8240-8248 (2008).

3. A. T. Koudehi, B. Mahjoubi, R. Mirzaei, S. Shabani, F. Mahjoubi, AKAP4, SPAG9 and NY-ESO-1 in Iranian Colorectal Cancer Patients as Probable Diagnostic and Prognostic Biomarkers. *Asian Pacific Journal of Cancer Prevention : APJCP* **19**, 463-469 (2018).

4. O. Kholmanskikh, A. Loriot, F. Brasseur, E. De Plaen, C. De Smet, Expression of BORIS in melanoma: Lack of association with MAGE-A1 activation. *International Journal of Cancer* **122**, 777-784 (2007).

5. S. Vatolin, Z. Abdullaev, S. D. Pack, P. T. Flanagan, M. Custer, D. I. Loukinov, E. Pugacheva, J. A. Hong, H. Morse, 3rd, D. S. Schrump, J. I. Risinger, J. C. Barrett, V. V. Lobanenkov, Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. *Cancer Res* **65**, 7751-7762 (2005).

6. C. Cuffel, J. P. Rivals, Y. Zaugg, S. Salvi, W. Seelentag, D. E. Speiser, D. Lienard, P. Monnier, P. Romero, L. Bron, D. Rimoldi, Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. *Int J Cancer* **128**, 2625-2634 (2011).

7. H. Takeuchi, D. L. Morton, D. Elashoff, D. S. B. Hoon, Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. *International journal of cancer. Journal international du cancer* **117**, 1032-1038 (2005).

8. L. Q. Zhang, J. Wang, F. Jiang, L. Xu, F. Y. Liu, R. Yin, Prognostic Value of Survivin in Patients with Non-Small Cell Lung Carcinoma: A Systematic Review with Meta-Analysis. *PLOS ONE* **7**, e34100 (2012).

9. I. J. Goossens-Beumer, E. C. Zeestraten, A. Benard, T. Christen, M. S. Reimers, R. Keijzer, C. F. Sier, G. J. Liefers, H. Morreau, H. Putter, A. L. Vahrmeijer, C. J. van de Velde, P. J. Kuppen, Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. *Br J Cancer* **110**, 2935-2944 (2014).

10. J. A. H. Ku, C. Kwak, H. S. Lee, H. K. Park, E. Lee, S. E. Lee, Expression of Survivin, a Novel Inhibitor of Apoptosis, in Superficial Transitional Cell Carcinoma of the Bladder. *The Journal of Urology* **171**, 631-635 (2004).

11. M. Uematsu, I. Ohsawa, T. Aokage, K. Nishimaki, K. Matsumoto, H. Takahashi, S. Asoh, A. Teramoto, S. Ohta, Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. *J Neurooncol* **72**, 231-238 (2005).

12. R. Zamparese, G. Pannone, A. Santoro, L. L. Muzio, F. Corsi, M. C. Pedicillo, E. L. Scillitani, S. Tortorella, S. Staibano, S. Piscuoglio, L. L. Russo, P. Bufo, Survivin Expression in Renal Cell Carcinoma. *Cancer Investigation* **26**, 929-935 (2008).

13. Z. Ali, R. Fisher, J. Larkin, *Targeted therapeutics in melanoma*. (2012), vol. 107, pp. 1663.

14. P. G. Coulie, P. Weynants, F. Lehmann, J. Herman, V. Brichard, T. Wölfel, A. V. Pel, E. De Plaen, F. Brasseur, T. Boon, Genes Coding for Tumor Antigens Recognized by Human Cytolytic T Lymphocytes. *Journal of Immunotherapy* **14**, 104-109 (1993).

15. Z. Chen, M. Li, Y. Yuan, Q. Wang, L. Yan, J. Gu, Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel. *Dis Colon Rectum* **53**, 31-38 (2010).

16. B. Yin, G. Liu, X. S. Wang, H. Zhang, Y. S. Song, B. Wu, Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder. *Urol Oncol* **30**, 886-892 (2012).

17. O. N. Syed, C. E. Mandigo, B. D. Killory, P. Canoll, J. N. Bruce, Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. *J Clin Neurosci* **19**, 1016-1021 (2012).

18. K. Yamanaka, H. Miyake, I. Hara, K. Gohji, S. Arakawa, S. Kamidono, Expression of MAGE genes in renal cell carcinoma. *International Journal of Molecular Medicine*, (1998).

19. R. Gutzmer, L. Rivoltini, E. Levchenko, A. Testori, J. Utikal, P. A. Ascierto, L. Demidov, J. J. Grob, R. Ridolfi, D. Schadendorf, P. Queirolo, A. Santoro, C. Loquai, B. Dreno, A. Hauschild, E. Schultz, T. P. Lesimple, N. Vanhoutte, B. Salaun, M. Gillet, S. Jarnjak, P. M. De Sousa Alves, J. Louahed, V. G. Brichard, F. F. Lehmann, Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. *ESMO Open* **1**, (2016).

20. S. Thongprasert, P.-C. Yang, J. S. Lee, R. Soo, O. Gruselle, A. Myo, J. Louahed, F. F. Lehmann, V. G. Brichard, T. Coche, The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients. *Lung Cancer* **101**, 137-144 (2016).

21. L. Dyrskjot, K. Zieger, T. Kissow Lildal, T. Reinert, O. Gruselle, T. Coche, M. Borre, T. F. Orntoft, Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. *Br J Cancer* **107**, 116-122 (2012).

22. E. Neumann, A. Engelsberg, J. Decker, S. Störkel, E. Jaeger, C. Huber, B. Seliger, Heterogeneous Expression of the Tumor-associated Antigens RAGE-1, PRAME, and Glycoprotein 75 in Human Renal Cell Carcinoma: Candidates for T-Cell-based Immunotherapies? *Cancer Research* **58**, 4090-4095 (1998).

23. H.-J. Heidebrecht, A. Claviez, M. L. Kruse, M. Pollmann, F. Buck, S. Harder, M. Tiemann, W. Dörffel, R. Parwaresch, Characterization and Expression of CT45 in Hodgkin's Lymphoma. *Clinical Cancer Research* **12**, 4804-4811 (2006).

24. Y. T. Chen, M. Hsu, P. Lee, S. J. Shin, P. Mhawech-Fauceglia, K. Odunsi, N. K. Altorki, C. J. Song, B. Q. Jin, A. J. Simpson, L. J. Old, Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. *Int J Cancer* **124**, 2893-2898 (2009).

25. Y. Akiyama, M. Komiyama, H. Miyata, M. Yagoto, T. Ashizawa, A. Iizuka, C. Oshita, A. Kume, M. Nogami, I. Ito, R. Watanabe, T. Sugino, K. Mitsuya, N. Hayashi, Y. Nakasu, K. Yamaguchi, Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients. *Oncol Rep* **31**, 1683-1690 (2014).

26. K. C. Piotti, T. Scognamiglio, R. Chiu, Y.-T. Chen, Expression of cancer/testis (CT) antigens in squamous cell carcinoma of the head and neck: Evaluation as markers of squamous dysplasia. *Pathology - Research and Practice* **209**, 721-726 (2013).

27. S.-Y. Lee, Y. Obata, M. Yoshida, E. Stockert, B. Williamson, A. A. Jungbluth, Y.-T. Chen, L. J. Old, M. J. Scanlan, Immunomic analysis of human sarcoma. *Proceedings of the National Academy of Sciences* **100**, 2651-2656 (2003).

28. M. Sun, W. Zhao, Y. Zeng, D. Zhang, Z. Chen, C. Liu, B. Wu, Fibrous sheath interacting protein 1 overexpression is associated with unfavorable prognosis in bladder cancer: a potential therapeutic target. *OncoTargets and therapy* **10**, 3949-3956 (2017).

29. G. Carolin, K. Michael, A. Tülin, D. Karl, P. Marleen, V. Anja, M.-H. Alicia, L. Michael, P. Bernward, L. Hans-Anton, S. S. C., S. Gerhard, H. Christoph, S. Ugur, T. Özlem, Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. *International Journal of Cancer* **118**, 2522-2528 (2006).

30. D. Atanackovic, I. Blum, Y. Cao, S. Wenzel, K. Bartels, C. Faltz, D. K. Hossfeld, S. Hegewisch-Becker, C. Bokemeyer, R. Leuwer, Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. *Cancer Biology & Therapy* **5**, 1218-1225 (2006).

31. D. Balafoutas, A. zur Hausen, S. Mayer, M. Hirschfeld, M. Jaeger, D. Denschlag, G. Gitsch, A. Jungbluth, E. Stickeler, Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. *BMC Cancer* **13**, 271 (2013).

32. A. Bergeron, V. Picard, H. LaRue, F. Harel, H. Hovington, L. Lacombe, Y. Fradet, High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. *Int J Cancer* **125**, 1365-1371 (2009).

33. G. Hatiboglu, M. Pritsch, S. Macher-Goeppinger, M. Zoller, J. Huber, A. Haferkamp, S. Pahernik, N. Wagener, M. Hohenfellner, Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma. *Scand J Urol* **47**, 311-322 (2013).

34. T. J. Meyer, S. Hartmann, G. Wohlleben, M. Brisam, A. Seher, A. C. Kübler, B. Polat, U. D. A. Müller-Richter, MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation. *Molecular and Clinical Oncology* **8**, 513-519 (2018).

35. O. Tureci, U. Sahin, C. Zwick, M. Koslowski, G. Seitz, M. Pfreundschuh, Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. *Proceedings of the National Academy of Sciences* **95**, 5211-5216 (1998).

36. U. Sahin, M. Koslowski, Ö. Türeci, T. Eberle, C. Zwick, B. Romeike, J.-R. Moringlane, K. Schwechheimer, W. Feiden, M. Pfreundschuh, Expression of Cancer Testis Genes in Human Brain Tumors. *Clinical Cancer Research* **6**, 3916-3922 (2000).

37. Y. Fradet, V. Picard, A. Bergeron, H. Larue, *Cancer-testis antigen expression in bladder cancer*. (2006), vol. 16, pp. 421-428.

38. M.-H. Lee, E.-I. Son, E. Kim, I.-S. Kim, M.-B. Yim, S.-P. Kim, Expression of Cancer-Testis Genes in Brain Tumors. *Journal of Korean Neurosurgical Society* **43**, 190-193 (2008).

39. L. Heidecker, F. Brasseur, M. Probst-Kepper, M. Gueguen, T. Boon, B. J. Van den Eynde, Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. *J Immunol* **164**, 6041-6045 (2000).

40. F. T. Zamuner, B. T. Karia, C. Z. de Oliveira, C. R. Santos, A. L. Carvalho, A. L. Vettore, A Comprehensive Expression Analysis of Cancer Testis Antigens in Head and Neck Squamous Cell Carcinoma Revels MAGEA3/6 as a Marker for Recurrence. *Mol Cancer Ther* **14**, 828-834 (2015).

41. B. Yin, Y. Zeng, X. Wang, G. Liu, M. Zhang, Y. Song, Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma. *International Journal of Clinical and Experimental Pathology* **7**, 4112-4119 (2014).

42. P. M. Alves, N. Levy, H. Bouzourene, S. Viatte, G. Bricard, M. Ayyoub, H. Vuilleumier, J. C. Givel, N. Halkic, D. E. Speiser, P. Romero, F. Levy, Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. *Cancer Immunol Immunother* **56**, 839-847 (2007).

43. C. Mengus, E. Schultz-Thater, J. Coulot, Z. Kastelan, E. Goluza, M. Coric, G. C. Spagnoli, T. Hudolin, MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas. *Int J Cancer* **132**, 2459-2463 (2013).

44. J. G. Mantilla, T. Antic, M. Tretiakova, GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics. *Hum Pathol* **66**, 152-158 (2017).

45. M. C. Lin, J. J. Lin, C. L. Hsu, H. F. Juan, P. J. Lou, M. C. Huang, GATA3 interacts with and stabilizes HIF-1α to enhance cancer cell invasiveness. *Oncogene* **36**, 4243 (2017).

46. A. Gerhardt, D. Usener, M. Keese, J. Sturm, D. Schadendorf, S. Eichmuller, Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. *Cancer Lett* **208**, 197-206 (2004).

47. S. Ugur, T. Özlem, C. Yao-Tseng, S. Gerhard, V.-H. Carlos, O. L. J., P. Michael, Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies. *International Journal of Cancer* **78**, 387-389 (1998).

48. Ö. Türeci, Y.-T. Chen, U. Sahin, A. O. Güre, C. Zwick, C. Villena, S. Tsang, G. Seitz, L. J. Old, M. Pfreundschuh, Expression ofSSX genes in human tumors. *International Journal of Cancer* **77**, 19-23 (1998).

49. A. J. Zendman, I. M. Cornelissen, U. H. Weidle, D. J. Ruiter, G. N. van Muijen, CTp11, a novel member of the family of human cancer/testis antigens. *Cancer Res* **59**, 6223-6229 (1999).

50. Y.-T. Chen, C. A Venditti, G. Theiler, B. Stevenson, C. Iseli, A. Gure, C. Jongeneel, L. J Old, A. J G Simpson, *Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein*. (2005), vol. 5, pp. 9.

51. B. Gaugler, B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, T. Boon, Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. *J Exp Med* **179**, 921-930 (1994).

52. A. Linder, H. Budihardjo-Welim, W. Velehorschi, T. Coche, O. Gruselle, D. D'Agostino, J. Louahed, F. Lehmann, V. G. Brichard, Prognostic value of MAGE-A3 and PRAME gene expression in non-small-cell lung cancer (NSCLC). *Journal of Clinical Oncology* **30**, 7056-7056 (2012).

53. A. Curioni-Fontecedro, N. Nuber, D. Mihic-Probst, B. Seifert, D. Soldini, R. Dummer, A. Knuth, M. van den Broek, H. Moch, Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients. *PLOS ONE* **6**, e21418 (2011).

54. A. O. Güre, E. Stockert, K. C. Arden, A. D. Boyer, C. S. Viars, M. J. Scanlan, L. J. Old, Y.-T. Chen, CT10: A new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. *International Journal of Cancer* **85**, 726-732 (2000).

55. P. Sharma, Y. Shen, S. Wen, D. F. Bajorin, V. E. Reuter, L. J. Old, A. A. Jungbluth, Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. *Clin Cancer Res* **12**, 5442-5447 (2006).

56. W.-L. Qiao, B.-W. Shi, Y.-D. Han, H.-M. Tang, J. Lin, H.-Y. Hu, Q. Lin, Testes-specific protease 50 as an independent risk factor for poor prognosis in patients with non-small cell lung cancer. *Oncology Letters* **15**, 8796-8804 (2018).

57. L. Zheng, G. Xie, G. Duan, X. Yan, Q. Li, High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma. *PLoS One* **6**, e22203 (2011).

58. P. Went, M. Vasei, L. Bubendorf, L. Terracciano, L. Tornillo, U. Riede, J. Kononen, R. Simon, G. Sauter, P. A. Baeuerle, Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. *British Journal of Cancer* **94**, 128-135 (2006).

59. A. Brunner, M. Prelog, I. Verdorfer, A. Tzankov, G. Mikuz, C. Ensinger, EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. *Journal of Clinical Pathology* **61**, 307-310 (2008).

60. P. Went, S. Dirnhofer, T. Salvisberg, M. B. Amin, S. D. Lim, P.-A. Diener, H. Moch, Expression of Epithelial Cell Adhesion Molecule (EpCam) in Renal Epithelial Tumors. *The American Journal of Surgical Pathology* **29**, 83-88 (2005).

61. S. Park, Y. Lim, D. Lee, B. Cho, Y.-J. Bang, S. Sung, H.-Y. Kim, D.-K. Kim, Y.-S. Lee, Y. Song, D.-I. Jeoung, Identification and characterization of a novel cancer/testis antigen gene CAGE-1. *Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression* **1625**, 173-182 (2003).

62. A. G. Dakshinamurthy, R. Ramesar, P. Goldberg, J. M. Blackburn, Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations. *Biotechnol J* **3**, 1417-1423 (2008).

63. H. Hasegawa, M. Mori, M. Haraguchi, H. Ueo, K. Sugimachi, T. Akiyoshi, Expression spectrum of melanoma antigen-encoding gene family members in colorectal carcinoma. *Arch Pathol Lab Med* **122**, 551-554 (1998).

64. V. Picard, A. Bergeron, H. Larue, Y. Fradet, MAGE-A9 mRNA and protein expression in bladder cancer. *Int J Cancer* **120**, 2170-2177 (2007).

65. M. H. Song, J. C. Ha, S. M. Lee, Y. M. Park, S. Y. Lee, Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. *Biochem Biophys Res Commun* **408**, 195-201 (2011).

66. M. J. Scanlan, C. M. Gordon, B. Williamson, S. Y. Lee, Y. T. Chen, E. Stockert, A. Jungbluth, G. Ritter, D. Jager, E. Jager, A. Knuth, L. J. Old, Identification of cancer/testis genes by database mining and mRNA expression analysis. *Int J Cancer* **98**, 485-492 (2002).

67. V. D. B. Pierre, Z. Yi, C. Pascal, S. Vincent, P. Christophe, S. E. S., C. Jacques, V. d. E. B. J., B. Francis, B. Thierry, Tumor-specific shared antigenic peptides recognized by human T cells. *Immunological Reviews* **188**, 51-64 (2002).

68. X. Ye, J. Xie, H. Huang, Z. Deng, Knockdown of MAGEA6 Activates AMP-Activated Protein Kinase (AMPK) Signaling to Inhibit Human Renal Cell Carcinoma Cells. *Cellular Physiology and Biochemistry* **43**, 1205-1218 (2017).

69. P. Boël, C. Wildmann, M. L. Sensi, R. Brasseur, J.-C. Renauld, P. Coulie, T. Boon, P. van der Bruggen, <em>BAGE</em>: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. *Immunity* **2**, 167-175 (1995).

70. Y. T. Chen, A. O. Gure, S. Tsang, E. Stockert, E. Jager, A. Knuth, L. J. Old, Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. *Proc Natl Acad Sci U S A* **95**, 6919-6923 (1998).

71. Zendman AJ, de Wit NJ, van Kraats AA, Weidle UH, Ruiter DJ, v. M. GN, Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma. *Melanoma Research* **11**, 451-459 (2001).

72. Q. Shan, X. Lou, T. Xiao, J. Zhang, H. Sun, Y. Gao, S. Cheng, L. Wu, N. Xu, S. Liu, A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. *Cancer Letters* **328**, 160-167 (2013).

73. E. Giesen, L. B. Jilaveanu, F. Parisi, Y. Kluger, R. L. Camp, H. M. Kluger, NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. *Oncotarget* **5**, 5209-5217 (2014).

74. B. Francis, R. Donata, L. Danielle, L. Bernard, C. Stefan, A. Flavio, S. Ludwig, V. Romain, B. André, H. Yves, V. Angelo, C. Marina, L. Thierry, D. Gérard, D. Rika, B. Marc, S. Xavier, S. Emile, D. Brigitte, J. Elke, K. Alex, C. Christine, S. Stefan, L. Jean-Marie, P. Pierre, P. Giorgio, L. Ferdy, C. Jean-Charles, B. Thierry, M. Marie, Expression of MAGE genes in primary and metastatic cutaneous melanoma. *International Journal of Cancer* **63**, 375-380 (1995).

75. J.-J. Patard, F. Brasseur, S. Gil-Diez, F. Radvanyi, M. Marchand, P. François, A. Abi-Aad, P. Van Cangh, C. C. Abbou, D. Chopin, T. Boon, Expression ofmage genes in transitional-cell carcinomas of the urinary bladder. *International Journal of Cancer* **64**, 60-64 (1995).

76. D. L. Scarcella, C. W. Chow, M. F. Gonzales, C. Economou, F. Brasseur, D. M. Ashley, Expression of MAGE and GAGE in High-Grade Brain Tumors: A Potential Target for Specific Immunotherapy and Diagnostic Markers. *Clinical Cancer Research* **5**, 335-341 (1999).

77. C. A. Glazer, I. M. Smith, S. Bhan, W. Sun, S. S. Chang, K. M. Pattani, W. Westra, Z. Khan, J. A. Califano, The Role of MAGEA2 in Head and Neck Cancer. *Archives of otolaryngology--head & neck surgery* **137**, 286-293 (2011).

78. Z. A. J.W., v. K. A. A., W. U. H., R. D. J., v. M. G. N.P., The XAGE family of cancer/testis-associated genes: Alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma. *International Journal of Cancer* **99**, 361-369 (2002).

79. Q. Shan, X. Lou, T. Xiao, J. Zhang, H. Sun, Y. Gao, S. Cheng, L. Wu, N. Xu, S. Liu, A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. *Cancer Lett* **328**, 160-167 (2013).

80. M. Freitas, S. Malheiros, J. N. Stavale, T. P. Biassi, F. T. Zamuner, M. de Souza Begnami, F. A. Soares, A. L. Vettore, Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. *Oncotarget* **4**, 636-646 (2013).

81. B. T. R. Karia, F. T. Zamuner, V. Carlin, C. Z. de Oliveira, A. L. Carvalho, A. L. Vettore, Expression and Prognostic Relevance of GAGE1 and XAGE1 Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma. *Curr Mol Med* **17**, 707-717 (2017).

82. S. Hartmann, L. Zwick, M. J. J. Scheurer, A. R. Fuchs, R. C. Brands, A. Seher, H. Bohm, A. C. Kubler, U. D. A. Muller-Richter, MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer. *Clin Oral Investig* **22**, 1477-1486 (2018).

83. S. Eichmuller, D. Usener, A. Jochim, D. Schadendorf, mRNA expression of tumor-associated antigens in melanoma tissues and cell lines. *Experimental Dermatology* **11**, 292-301 (2002).

84. K. Mashino, N. Sadanaga, F. Tanaka, H. Yamaguchi, H. Nagashima, H. Inoue, K. Sugimachi, M. Mori, Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. *Br J Cancer* **85**, 713-720 (2001).

85. C. Barrow, J. Browning, D. MacGregor, I. D. Davis, S. Sturrock, A. A. Jungbluth, J. Cebon, Tumor antigen expression in melanoma varies according to antigen and stage. *Clin Cancer Res* **12**, 764-771 (2006).

86. Y. Shigematsu, T. Hanagiri, H. Shiota, K. Kuroda, T. Baba, M. Mizukami, T. So, Y. Ichiki, M. Yasuda, T. So, M. Takenoyama, K. Yasumoto, Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. *Lung Cancer* **68**, 105-110 (2010).

87. B. Alain, P. Valérie, L. Hélène, H. Francois, H. Hélène, L. Louis, F. Yves, High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. *International Journal of Cancer* **125**, 1365-1371 (2009).

88. J.-R. Tsai, I.-W. Chong, Y.-H. Chen, M.-J. Yang, C.-C. Sheu, H.-C. Chang, J.-J. Hwang, J.-Y. Hung, S.-R. Lin, Differential expression profile of MAGE family in non-small-cell lung cancer. *Lung Cancer* **56**, 185-192 (2007).

89. S. Hartmann, U. Kriegebaum, N. Kuchler, G. Lessner, R. C. Brands, C. Linz, T. Schneider, A. C. Kubler, U. D. Muller-Richter, Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: prognostic value of MAGE-A subgroups for treatment success. *J Craniomaxillofac Surg* **41**, 623-629 (2013).

90. C. Lurquin, C. De Smet, F. Brasseur, F. Muscatelli, V. Martelange, E. De Plaen, R. Brasseur, A. P. Monaco, T. Boon, Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. *Genomics* **46**, 397-408 (1997).

91. K. M. Pattani, E. Soudry, C. A. Glazer, M. F. Ochs, H. Wang, J. Schussel, W. Sun, P. Hennessey, W. Mydlarz, M. Loyo, S. Demokan, I. M. Smith, J. A. Califano, MAGEB2 is Activated by Promoter Demethylation in Head and Neck Squamous Cell Carcinoma. *PLoS ONE* **7**, e45534 (2012).

92. V. Martelange, C. De Smet, E. De Plaen, C. Lurquin, T. Boon, Identification on a human sarcoma of two new genes with tumor-specific expression. *Cancer Res* **60**, 3848-3855 (2000).

93. M. Mathieu, R. Rees, E. Tartour, R. Ferris, C. Badoual, S. McArdle, HAGE, a novel antigen for potential immunotherapy treatment against Head and Neck cancer. *Cancer Research* **68**, LB-128-LB-128 (2008).

94. A. Loriot, T. Boon, C. De Smet, Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. *Int J Cancer* **105**, 371-376 (2003).

95. D. Yuki, Y. M. Lin, Y. Fujii, Y. Nakamura, Y. Furukawa, Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers. *Oncol Rep* **12**, 275-280 (2004).

96. T. Ono, T. Kurashige, N. Harada, Y. Noguchi, T. Saika, N. Niikawa, M. Aoe, S. Nakamura, T. Higashi, A. Hiraki, H. Wada, H. Kumon, L. J. Old, E. Nakayama, Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. *PNAS* **98**, 3282-3287 (2001).

97. M. Koslowski, Ö. Türeci, C. Bell, P. Krause, H.-A. Lehr, J. Brunner, G. Seitz, F. O. Nestle, C. Huber, U. Sahin, Multiple Splice Variants of Lactate Dehydrogenase C Selectively Expressed in Human Cancer. *Cancer Research* **62**, 6750-6755 (2002).